Literature DB >> 19421918

An economic evaluation of topical treatments for actinic keratosis.

Dominic Muston1, Anthony Downs, Vincent Rives.   

Abstract

Actinic keratoses (AK) commonly occur as lesions, in sun-exposed areas. Various treatment modalities exist for their removal. We assessed the cost-effectiveness in 2007 of topical treatments (5-fluorouracil, imiquimod) and photodynamic therapy with methyl aminolevulinate (MAL-PDT) for AK under the perspective of the UK National Health Service (NHS) in England and Wales over two lines of treatment. We used a decision tree analytical approach. Efficacy data were taken from published trial literature for two investigator-assessed outcomes: 'complete clinical response' and 'excellent cosmetic outcome'. MAL-PDT at first line followed by various second-line treatments provided the greatest probability of complete clinical response (91.7%), but MAL-PDT at first line followed by further MAL-PDT as the second-line treatment provided the greatest probability of excellent cosmetic outcome (73.6%). The cost of MAL-PDT was 437 pounds sterling after two lines of treatment if MAL-PDT was that second-line treatment or 418 pounds sterling if various treatments were offered at second line. The probabilistic analysis produced consistent results. Based on this model, the costs and effectiveness of MAL-PDT in the UK NHS compare well with other treatments for AK.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19421918     DOI: 10.1080/09546630902887211

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  6 in total

1.  A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.

Authors:  Keith Tolley; Danny Kemmett; Signe Thybo; Ruth Nasr; Helen Smethurst
Journal:  Eur J Health Econ       Date:  2015-03-21

2.  Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Pharmacoeconomic considerations in treating actinic keratosis.

Authors:  Marjorie V Neidecker; Mary Lynn Davis-Ajami; Rajesh Balkrishnan; Steven R Feldman
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Histopathological analysis of the therapeutic response to cryotherapy with liquid nitrogen in patients with multiple actinic keratosis.

Authors:  Marina Câmara de Oliveira; Flávia Trevisan; Clovis Antônio Lopes Pinto; Célia Antônia Xavier; Jaqueline Campoi Calvo Lopes Pinto
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

5.  Cost-utility of first-line actinic keratosis treatments in Finland.

Authors:  Erkki J Soini; Taru Hallinen; Anna-Leena Sokka; Kari Saarinen
Journal:  Adv Ther       Date:  2015-05-26       Impact factor: 3.845

6.  A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.

Authors:  Stefan Vegter; Keith Tolley
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.